Skip to main content Help with accessibility Skip to main navigation

Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, biological agents in the management of

CCG Approval Status:

Date Added: 28 - Sep - 2022
Body System:

The Pan Mersey Area Prescribing Committee recommends the use of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ixekizumab in the management of ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (NRAxSpA) in accordance with NICE TA383, NICE TA407, NICE TA497, NICE TA718 and NICE TA719..

Prescribing pathway